Cambridge Investment Research Advisors
SLN icon

Cambridge Investment Research Advisors’s Silence Therapeutics SLN Stock Holding History

Cambridge Investment Research Advisors’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,194
Closed -$53K – 3946
2025
Q3 		$53K Hold
10,194
– – ﹤0.01% 3656
2025
Q2 		$59K Buy
+10,194
New +$43.7K ﹤0.01% 3525

Other funds holding SLN

TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Cambridge Investment Research Advisors's SLN Position: Q4 2025 in Review

Cambridge Investment Research Advisors sold out of Silence Therapeutics (SLN) in Q4 2025, closing a stake of 10,194 shares — an estimated $53K sold.

Cambridge Investment Research Advisors first reported a position in SLN in Q2 2025 and held it in 2 quarters. The position peaked at $59K in Q2 2025. 58 funds tracked by Wall St. Rank hold SLN as of Q4 2025.

  • Cambridge Investment Research Advisors reported no remaining Silence Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 10,194 Silence Therapeutics shares in Q4 2025, an estimated $53K.
  • Cambridge Investment Research Advisors first reported a position in Silence Therapeutics in Q2 2025 and held it in 2 quarters.
  • Cambridge Investment Research Advisors's Silence Therapeutics position peaked at $59K in Q2 2025.
  • 58 funds tracked by Wall St. Rank held Silence Therapeutics as of Q4 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2025, filed 5 Feb 2026.